Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Henry Meds vs Rixa Health

Henry Meds
Graded #46

Higher grade

vs+16.799999999999997
Rixa Health
Graded #320

Lower grade

The verdict

Henry Meds takes it — 77.3/100 to 60.5/100.

Henry Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A flat-fee compounded pioneer — simple, but priced at the higher end of the board now.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHenry Meds +27
72
45
Dose & formulationHenry Meds +29
80
51
Clinical oversightRixa Health +5
80
85
Labs & monitoringHenry Meds +15
78
63
FulfillmentEven
78
78
Contract termsHenry Meds +37
78
41
Henry Meds · left barRixa Health · right bar

The numbers

MetricHenry MedsRixa Health
WeighScore77.3/10060.5/100
GradeC+C
Scorecard rank#46#320
Semaglutide$249/moNot disclosed
Tirzepatide$349/moNot disclosed
CoverageMulti-stateAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Henry Meds

Graded #46 · C+

Strengths

  • Simple flat-fee model
  • Established brand
  • Both molecules

Where it loses points

  • Higher pricing than newer entrants
  • Compounded only
Rixa Health

Graded #320 · C

Strengths

  • Functional-medicine, root-cause clinical approach
  • Compounded and oral semaglutide plus tirzepatide offered
  • Board-certified DO and FNP providers with years of experience
  • Medication bundled with visits into a single price
  • No charge until after approval

Where it loses points

  • No public monthly pricing; quoted only during consultation
  • Relies on compounded GLP-1, which is not FDA-approved as a finished drug
  • A handful of states still listed as coming soon
  • Branded GLP-1 medications are not the primary offering
  • Requires ongoing monthly follow-up commitment

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard